Literature DB >> 20506257

Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders.

Karen B Onel1, Kenan Onel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20506257     DOI： 10.1002/acr.20228

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  5 in total

1.  Juvenile idiopathic arthritis: management and therapeutic options.

Authors:  Natasha M Ruth; Murray H Passo
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

2.  Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.

Authors:  Timothy Beukelman; Kevin Haynes; Jeffrey R Curtis; Fenglong Xie; Lang Chen; Christina J Bemrich-Stolz; Elizabeth Delzell; Kenneth G Saag; Daniel H Solomon; James D Lewis
Journal:  Arthritis Rheum       Date:  2012-02-10

Review 3.  Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 4.  What is the background incidence of malignancy in children with rheumatic disease?

Authors:  Melissa L Mannion; Timothy Beukelman
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 5.  Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2013-01       Impact factor: 11.431
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.